<DOC>
	<DOCNO>NCT01345526</DOCNO>
	<brief_summary>The aim Phase 2 , two-arm , randomize , double blind placebo control study evaluate efficacy combination therapy doxycycline Vitamin K1 compare doxycycline plus placebo prevention acne-like skin rash mCRC patient receive first line cetuximab treatment .</brief_summary>
	<brief_title>Efficacy Safety Prophylactic Use Doxycycline +/- Vitamin K Cream</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Written informed consent must give Patient ≥ 18 year Histologically proven measurable metastatic adenocarcinoma colon rectum ( accord modify RECIST criterion v.1.1 ) Patients eligible Erbitux FOLFIRI treatment KRas wild type tumour Metastatic disease Life expectancy least 12 week WHO performance status 0 1 Effective contraception male female patient risk conception exists Adequate organ function Adequate bone marrow , hepatic renal function ( Hemoglobin &gt; 10.0 g/dL , platelet count &gt; 100 x 109/L , absolute neutrophil count &gt; 1.5 x 109/L ; ALAT , ASAT &lt; 2.5 x ULN ( upper limit normal range ) &lt; 5x ULN case liver metastasis ; Alkaline phosphatase &lt; 2.5 x ULN ; Total bilirubin &lt; 1.5 x ULN ; Creatinine clearance &gt; 50 mL/min ( calculate accord Cockcroft Gault formula ) ) . Prior treatment metastatic disease ( adjuvant therapy 5FU/oxaliplatin base regimen ) allow stop 6 month prior registration study Prior treatment EGFR inhibitor Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior study entry Administration investigational drug agent/procedure , i.e . participation another trial within 4 week begin treatment study drug Concurrent chronic systemic immune therapy , chemotherapy , radiation therapy hormone therapy indicate study protocol Any active dermatological condition &gt; grade 1 baseline possibly interfere influence result conduct present study Brain metastasis ( know suspect ) Significant impairment intestinal resorption ( e.g . chronic diarrhea , inflammatory bowel disease ) Any uncontrolled concomitant illness , include serious uncontrolled intercurrent infection Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction within last twelve month , significant arrhythmia ) Known allergy adverse reaction study drug relate compound . Any organ allograft require immunosuppressive therapy . Pregnancy ( absence confirm serum/urine beta human chorion gonadotrophin ( HCG ) ) breastfeeding . Other previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix surgically cure adequately treat . Known drug abuse / alcohol abuse Legal incapacity limit legal capacity Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Medical psychological condition , opinion investigator , would permit patient complete study meaningfully sign informed consent . Known M. Meulengracht ( Gilbert´s disease ) DPDinsufficiency Known coagulation disorder Ongoing plan treatment coumarin derivates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>